Analysts See $-0.19 EPS for OncoSec Medical Incorporated (ONCS)

February 24, 2018 - By Henry Gaston

 Analysts See $ 0.19 EPS for OncoSec Medical Incorporated (ONCS)

Analysts expect OncoSec Medical Incorporated (NASDAQ:ONCS) to report $-0.19 EPS on March, 15.They anticipate $0.08 EPS change or 29.63 % from last quarter’s $-0.27 EPS. The stock increased 0.56% or $0.01 during the last trading session, reaching $1.78. About 655,359 shares traded. OncoSec Medical Incorporated (NASDAQ:ONCS) has declined 34.57% since February 24, 2017 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, June 2 with “Buy”. On Thursday, July 21 the stock rating was reinitiated by Rodman & Renshaw with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. Maxim Group maintained the stock with “Buy” rating in Thursday, June 8 report. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 9. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) earned “Buy” rating by Noble Financial on Tuesday, June 13. The firm earned “Buy” rating on Friday, June 2 by Maxim Group. The rating was maintained by H.C. Wainwright on Friday, January 19 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, December 15. H.C. Wainwright maintained OncoSec Medical Incorporated (NASDAQ:ONCS) on Thursday, November 9 with “Buy” rating.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $76.44 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

More important recent OncoSec Medical Incorporated (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Receives $9.3 Million Warrant Exercise” on November 13, 2017, also Prnewswire.com published article titled: “This Morning’s Technical Outlook on Biotech Stocks — NewLink Genetics, OHR …”, Prnewswire.com published: “OncoSec Medical Incorporated Announces Closing of $23.0 Million Public …” on February 06, 2018. More interesting news about OncoSec Medical Incorporated (NASDAQ:ONCS) was released by: Prnewswire.com and their article: “OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: